Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Regularly reviewing your retirement plan is essential for long-term success. Find out when to make those important assessments.
20,077 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A surge in triple-leveraged ETFs has driven notional exposure to about $500 billion, intensifying daily volatility an...
Eli Lilly stock could advance in the second half of 2026 as Foundayo gains traction and the GLP-1 franchise shines, b...
A cooler June CPI print sparked a risk-on bid in semiconductors, with AMD surging and Intel climbing as investors bet...
JPMorgan Chase delivered a record quarterly performance, yet Jamie Dimon cautioned that the current market sprint cou...
Morgan Stanley's latest bottom up view argues that AI infrastructure demand will outpace supply, turning the Nebius s...
American Airlines is set to report July earnings, and investors will scrutinize demand signals, guidance, and cost tr...
Investors gauge SpaceX’s potential public listing amid a cautious IPO market. History from Meta’s debut suggests hype...
Investors chasing SpaceX-style wins without a private bet must weigh public players carefully. This guide compares AS...
Apple accelerates its cash-return program with a fresh buyback authorization and a dividend bump, underscoring a disc...
A bold forecast from Nvidia's founder centers on an AI spending boom. This article breaks down the rationale, the mat...
Mark Cuban is reviving the debate over wage inequality by urging companies to grant stock to every worker. His pitch ...